AMENDMENT TO THE EMPLOYMENT AGREEMENTEmployment Agreement • November 4th, 2021 • Acceleron Pharma Inc • Biological products, (no disgnostic substances)
This Amendment (“Amendment”), effective as of September 29, 2021, by and between Acceleron Pharma Inc., a Delaware corporation (“Acceleron”), and Kevin McLaughlin, SVP, Chief Financial Officer (the “Executive”), amends that certain Employment Agreement between Executive and Acceleron, dated as of February 13, 2014, as amended (“Agreement”). Together Acceleron and Executive are the “Parties” and each is a “Party”.
